fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Insulin injection, human biosynthetic

All injection strengths: general benefit

Entuzity KwikPen · DIN 02466864 · 500U/mL · injection solution-pre-filled pen 2x3mL Pk

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Entuzity KwikPen · DIN 02466864 Manufacturer: Eli Lilly Canada Inc.; listing date 2022-04-29 Health Canada: Marketed since 2017-10-20 · brand ENTUZITY KWIKPEN · ATC A10AD01 INSULIN (HUMAN) · form Solution · route Subcutaneous · ingredients INSULIN INJECTION HUMAN BIOSYNTHETIC 500 UNIT/ML · company Eli lilly canada inc · schedule Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Entuzity KwikPen: Formulary list price $116.50 per unit (the source does not state the unit; exact figure $116.5000). What the ministry pays, not the patient.

Ministry pays: $116.5000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02466864)

Source record
DIN 02466864: Entuzity KwikPen Raw flags: insOH=Y, sec3=Y Item: 682010048; group id 773; item number 1885; lccId None; manufacturer id LIL Source form: Inj Sol-Pref Pen 2x3mL Pk; strength: 500U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $116.5000; ministry $116.5000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02466864 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95524
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466864
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10A): coverage varies; not interchangeable

  • Insulin zinc crystalline human biosynthetic rdna origin (Humulin Regular): general benefit
  • Insulin aspart (NovoRapid): general benefit, limited Use 646
  • Insulin glulisine dna origin (Apidra): general benefit
  • Insulin human biosynthetic (Novolin ge Toronto): general benefit
  • Insulin lispro (Humalog): general benefit, limited Use 646
Other drugs in the same formulary class (68:20:10 Insulins (Rapid Acting)) and how they are covered

Matched class: 68:20:10 Insulins (Rapid Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC Some products covered without a code (check the product listing): INSULIN ASPART, INSULIN LISPRO 68:20:10 Insulins (Rapid Acting)

INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN ASPART

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5X3mL Pref Pen Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk

INSULIN GLULISINE (DNA ORIGIN)

· 3 products · General benefit · strengths: 100U/mL · Inj 5x3mL Cart ClickStar Pen, Inj Sol-10mL Vial, Inj Sol-5x3mL SoloSTAR Pref Pen

INSULIN HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN LISPRO

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL, 200U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk, Inj Sol-Pref Pen 5x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:10
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE • ENTUZITY is a concentrated human insulin indicated to improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day. • The safety and efficacy of ENTUZITY used in combination with other insulins has not been determined. • The safety and efficacy of ENTUZITY delivered by continuous subcutaneous infusion has not been determined. • ENTUZITY should not be used for the treatment of emergencies such as diabetic coma and pre-coma and patients with diabetes undergoing surgeries. Pediatrics (<18 years of age): No studies of ENTUZITY have been conducted in the pediatric population (see WARNINGS AND PRECAUTIONS, Special Populations). ENTUZITY KwikPen Page 3 of 40 Geriatrics (>65 years of age) There is limited evidence available in geriatric patients aged 65 to ≤75. Patients >75 years of age have not been studied (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00060561.PDF PM date: March 26, 2021 Source product: ENTUZITY KWIKPEN; DIN 02466864; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.